Extreme growth factor signalling can promote oestrogen receptor-α loss: Therapeutic implications in breast cancer

Breast Cancer Research

Volumn 6, Issue 4, 2004, Pages 162-163

  Gee, Julia M W ^a   Giles, Martin G ^a   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; GROWTH PROMOTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PARTHENOLIDE; RAF PROTEIN; S6 KINASE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CELL GROWTH; CYTOPLASM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

BREAST NEOPLASMS; CYTOPLASM; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; GROWTH SUBSTANCES; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN-TYROSINE KINASES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 4344626023     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr904     Document Type: Article

References (10)

1. Parl FF: Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer. Pharmacogenomics J 2003, 3:251-253.
2. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE: Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2003, 2:552-556.
3. Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of MAPK is responsible for ERα downregulation in breast cancer cells: the role of NFκB. Mol Endocrinol 2004, 18:1396-1410 [Epub 2004 Mar 31]
4. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB, Stoica A: Heregulin-β1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 2003, 10:2073-2087.
5. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-2359.
6. Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri H: Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. Br J Cancer 2004, 90:853-859.
7. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM: Non-endocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-354S.
8. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr.: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997, 17:3629-3639.
9. Munzone E, Nole F, Renne G, Balduzzi A, Sanna G, Corsetto L, Goldhirsch A: Reverting estrogen receptor (ER) negative phenotype in advanced breast cancer patients over-expressing HER2 after treatment with trastuzumab plus chemotherapy. Proc Am Soc Clin Oncol 2003, 22:848 [Abstract 3409].
10. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM: Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 2002, 21:7883-7890.